Evotec SE EVO 深 滬
等待開盤 03-26 09:30:00 美东时间
2.52
+0.180
+7.69%
華盛通- 最 高2.57
- 今 開2.53
- 成交量 13.47万股
- 最 低 2.4761
- 昨 收 2.34
- 總市值 8.96亿
- 52周最高 4.80
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 2.308
- 委 比 68.33%
- 總股本 3.55亿
- 歷史最高 25.29
- 量 比 1.39
- 振 幅 4.01%
- 歷史最低 2.308
- 每 手 1
- 風險率 0.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Evotec receives USD 10 million milestone payment from Bristol Myers Squibb after Phase 1 study start
Evotec receives USD 10 million milestone payment from Bristol Myers Squibb after Phase 1 study start Bristol Myers Squibb started a Phase 1 study of BMS-986506, a CELMoD drug candidate developed under its protein degradation partnership with Evotec. Evotec will receive a milestone payment of USD 10
03-19 14:36
Evotec to receive USD 10 million milestone as BMS starts Phase 1 trial of BMS-986506 in renal cell carcinoma
Evotec to receive USD 10 million milestone as BMS starts Phase 1 trial of BMS-986506 in renal cell carcinoma Bristol Myers Squibb initiated a Phase 1 clinical study of BMS-986506 in advanced clear cell renal cell carcinoma, with dosing of the first patient reported. The study evaluates BMS-986506, d
03-19 14:35
Evotec to receive USD 10 million milestone as BMS starts Phase 1 study of BMS-986506
Evotec to receive USD 10 million milestone as BMS starts Phase 1 study of BMS-986506 Bristol Myers Squibb initiated a Phase 1 clinical study of BMS-986506 in advanced clear cell renal cell carcinoma. Evotec is set to receive a USD 10 million milestone payment tied to the study initiation. Disclaimer
03-19 14:32
Evotec Restructuring Aims To Improve Profitability After Transition Year
Evotec launches transformation plan, targeting 75 million euros in savings by 2027 and revenue above 1 billion euros by 2030.
03-11 02:27
Why Zevra Therapeutics Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA, SOAR, MTEN, MDCX, NXGL, ABTC, and VALN. Losers include GSIW, POM, ARQ, RAIL, and NTZ.
03-10 16:42
Evotec SE Publishes Corporate Presentation on Pioneering Drug Discovery and Financials
Evotec SE Publishes Corporate Presentation on Pioneering Drug Discovery and Financials Evotec SE released a company presentation outlining its strategy for mid-term value creation across four levers: above-market growth with improved earnings quality, operational excellence through cost-out and prod
03-05 20:24
Davita Posts Upbeat Q4 Earnings, Joins Woodward, Terawulf And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining more than 150 points o...
02-03 22:55
JPMorgan Chase & Co. decreases total voting rights in Evotec SE
JPMorgan Chase & Co. decreases total voting rights in Evotec SE JPMorgan Chase & Co. has decreased its total percentage of voting rights in Evotec SE from 4.73% to 4.45%, reflecting a reduction of 0.28 percentage points compared to the previous notification. Disclaimer: This news brief was created b
01-21 17:50
Evotec’s Just – Evotec Biologics Wins Gates Foundation Grant to Advance AI-Optimised Affordable Biologics
An announcement from Evotec AG ( ($EVO) ) is now available. On 8 January 2026, ...
01-08 23:27
Evotec Biologics wins grant for AI-driven mAb optimization
Evotec SE (EVO) (EVOTF) Thursday reported that its Seattle-based subsidiary, Just-Evotec Biologics, has received a new grant from the Gates Foundation to enable global access to biotherapeutics utiliz...
01-08 15:01
公司簡介
公司名稱
|
Evotec SE
|
行業分類
|
Pharmaceuticals: Major
|
業務描述
|
Evotec SE is a life science company, which engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the Shared R&D and Justa€“Evotec Biologics segments. The Shared R&D segment includes drug discovery and development services and solutions. The Justa€“Evotec Biologics segment provides services related to designing, discovering, developing, and manufacturing of modern biotherapeutics. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, Charles Weissmann, and Nobel Laureate on December 8, 1993 and is headquartered in Hamburg, Germany.
|
Evotec receives USD 10 million milestone payment from Bristol Myers Squibb after Phase 1 study start
Evotec receives USD 10 million milestone payment from Bristol Myers Squibb after Phase 1 study start Bristol Myers Squibb started a Phase 1 study of BMS-986506, a CELMoD drug candidate developed under its protein degradation partnership with Evotec. Evotec will receive a milestone payment of USD 10
03-19 14:36
Evotec to receive USD 10 million milestone as BMS starts Phase 1 trial of BMS-986506 in renal cell carcinoma
Evotec to receive USD 10 million milestone as BMS starts Phase 1 trial of BMS-986506 in renal cell carcinoma Bristol Myers Squibb initiated a Phase 1 clinical study of BMS-986506 in advanced clear cell renal cell carcinoma, with dosing of the first patient reported. The study evaluates BMS-986506, d
03-19 14:35
Evotec to receive USD 10 million milestone as BMS starts Phase 1 study of BMS-986506
Evotec to receive USD 10 million milestone as BMS starts Phase 1 study of BMS-986506 Bristol Myers Squibb initiated a Phase 1 clinical study of BMS-986506 in advanced clear cell renal cell carcinoma. Evotec is set to receive a USD 10 million milestone payment tied to the study initiation. Disclaimer
03-19 14:32
Evotec Restructuring Aims To Improve Profitability After Transition Year
Evotec launches transformation plan, targeting 75 million euros in savings by 2027 and revenue above 1 billion euros by 2030.
03-11 02:27
Why Zevra Therapeutics Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA, SOAR, MTEN, MDCX, NXGL, ABTC, and VALN. Losers include GSIW, POM, ARQ, RAIL, and NTZ.
03-10 16:42
Evotec SE Publishes Corporate Presentation on Pioneering Drug Discovery and Financials
Evotec SE Publishes Corporate Presentation on Pioneering Drug Discovery and Financials Evotec SE released a company presentation outlining its strategy for mid-term value creation across four levers: above-market growth with improved earnings quality, operational excellence through cost-out and prod
03-05 20:24
Davita Posts Upbeat Q4 Earnings, Joins Woodward, Terawulf And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining more than 150 points o...
02-03 22:55
JPMorgan Chase & Co. decreases total voting rights in Evotec SE
JPMorgan Chase & Co. decreases total voting rights in Evotec SE JPMorgan Chase & Co. has decreased its total percentage of voting rights in Evotec SE from 4.73% to 4.45%, reflecting a reduction of 0.28 percentage points compared to the previous notification. Disclaimer: This news brief was created b
01-21 17:50
Evotec’s Just – Evotec Biologics Wins Gates Foundation Grant to Advance AI-Optimised Affordable Biologics
An announcement from Evotec AG ( ($EVO) ) is now available. On 8 January 2026, ...
01-08 23:27
Evotec Biologics wins grant for AI-driven mAb optimization
Evotec SE (EVO) (EVOTF) Thursday reported that its Seattle-based subsidiary, Just-Evotec Biologics, has received a new grant from the Gates Foundation to enable global access to biotherapeutics utiliz...
01-08 15:01
派息除權日
|
每股總股息
| 派息日期 |
2019-01-11
|
0.07
|
2019-01-22
|
2018-12-12
|
0.05
|
2018-12-20
|
2018-11-08
|
0.05
|
2018-11-19
|
2018-10-10
|
0.05
|
2018-10-18
|
2018-09-13
|
0.05
|
2018-09-21
|
2018-08-10
|
0.05
|
2018-08-20
|
2018-07-11
|
0.05
|
2018-07-19
|
2018-06-08
|
0.05
|
2018-06-18
|
2018-05-10
|
0.05
|
2018-05-18
|
2018-04-11
|
0.05
|
2018-04-19
|
2018-03-09
|
0.05
|
2018-03-19
|
2018-02-09
|
0.05
|
2018-02-20
|
2018-01-11
|
0.05
|
2018-01-19
|
2017-12-08
|
0.05
|
2017-12-18
|
2017-11-10
|
0.05
|
2017-11-20
|
2017-10-11
|
0.05
|
2017-10-19
|
2017-09-08
|
0.05
|
2017-09-18
|
2017-08-09
|
0.05
|
2017-08-18
|
2017-07-11
|
0.05
|
2017-07-20
|
2017-06-08
|
0.05
|
2017-06-19
|
2017-05-09
|
0.05
|
2017-05-18
|
2017-04-11
|
0.05
|
2017-04-20
|
2017-03-09
|
0.05
|
2017-03-20
|
2017-02-09
|
0.05
|
2017-02-21
|
2017-01-11
|
0.05
|
2017-01-20
|
2016-12-08
|
0.05
|
2016-12-19
|
2016-11-09
|
0.05
|
2016-11-21
|
2016-10-11
|
0.05
|
2016-10-20
|
2016-09-08
|
0.05
|
2016-09-19
|
2016-08-09
|
0.05
|
2016-08-18
|
2016-07-07
|
0.06
|
2016-07-18
|
2016-06-09
|
0.06
|
2016-06-20
|
2016-05-10
|
0.06
|
2016-05-19
|
2016-04-07
|
0.06
|
2016-04-18
|
2016-03-09
|
0.06
|
2016-03-18
|
2016-02-09
|
0.06
|
2016-02-18
|
2016-01-12
|
0.06
|
2016-01-21
|
2015-12-09
|
0.06
|
2015-12-18
|
2015-11-10
|
0.06
|
2015-11-20
|
2015-10-08
|
0.06
|
2015-10-20
|
2015-09-09
|
0.06
|
2015-09-18
|
2015-08-11
|
0.06
|
2015-08-20
|
2015-07-09
|
0.06
|
2015-07-20
|
2015-06-09
|
0.06
|
2015-06-18
|
2015-05-07
|
0.06
|
2015-05-18
|
2015-04-09
|
0.06
|
2015-04-20
|
2015-03-10
|
0.06
|
2015-03-19
|
2015-02-10
|
0.06
|
2015-02-19
|
2015-01-08
|
0.06
|
2015-01-20
|
2014-12-09
|
0.06
|
2014-12-18
|
2014-11-10
|
0.06
|
2014-11-20
|
2014-10-08
|
0.06
|
2014-10-20
|
2014-09-10
|
0.06
|
2014-09-19
|
2014-08-07
|
0.06
|
2014-08-18
|
2014-07-08
|
0.06
|
2014-07-17
|
2014-06-06
|
0.06
|
2014-06-17
|
2014-05-08
|
0.06
|
2014-05-19
|
2014-04-08
|
0.06
|
2014-04-17
|
2014-03-06
|
0.06
|
2014-03-17
|
2014-02-06
|
0.06
|
2014-02-18
|
2014-01-08
|
0.06
|
2014-01-17
|
2013-12-06
|
0.06
|
2013-12-17
|
2013-11-07
|
0.06
|
2013-11-19
|
2013-10-08
|
0.06
|
2013-10-17
|
2013-09-06
|
0.06
|
2013-09-17
|
2013-08-08
|
0.06
|
2013-08-19
|
2013-07-08
|
0.06
|
2013-07-17
|
2013-06-06
|
0.06
|
2013-06-17
|
2013-05-08
|
0.06
|
2013-05-17
|
2013-04-08
|
0.06
|
2013-04-17
|
2013-03-07
|
0.06
|
2013-03-18
|
2013-02-07
|
0.06
|
2013-02-19
|
2013-01-08
|
0.06
|
2013-01-17
|
2012-12-06
|
0.07
|
2012-12-17
|
2012-11-08
|
0.07
|
2012-11-20
|
2012-10-09
|
0.07
|
2012-10-18
|
2012-09-06
|
0.07
|
2012-09-17
|
2012-08-08
|
0.07
|
2012-08-17
|
2012-07-06
|
0.07
|
2012-07-17
|
2012-06-07
|
0.07
|
2012-06-18
|
2012-05-08
|
0.07
|
2012-05-17
|
2012-04-09
|
0.07
|
2012-04-18
|
2012-03-08
|
0.07
|
2012-03-19
|
2012-02-08
|
0.07
|
2012-02-17
|
2012-01-06
|
0.07
|
2012-01-17
|
2011-12-08
|
0.07
|
2011-12-19
|
2011-11-08
|
0.07
|
2011-11-17
|
2011-10-06
|
0.07
|
2011-10-18
|
2011-09-08
|
0.07
|
2011-09-19
|
2011-08-08
|
0.07
|
2011-08-17
|
2011-07-07
|
0.07
|
2011-07-18
|
2011-06-08
|
0.07
|
2011-06-17
|
2011-05-06
|
0.07
|
2011-05-17
|
2011-04-07
|
0.07
|
2011-04-18
|
2011-03-08
|
0.07
|
2011-03-17
|
2011-02-08
|
0.07
|
2011-02-17
|
2011-01-06
|
0.07
|
2011-01-18
|
2010-12-08
|
0.07
|
2010-12-17
|
2010-11-08
|
0.07
|
2010-11-17
|
2010-10-06
|
0.07
|
2010-10-18
|
2010-09-08
|
0.07
|
2010-09-17
|
2010-08-06
|
0.07
|
2010-08-17
|
2010-07-08
|
0.07
|
2010-07-19
|
2010-06-08
|
0.07
|
2010-06-17
|
2010-05-06
|
0.07
|
2010-05-17
|
2010-04-08
|
0.07
|
2010-04-19
|
2010-03-08
|
0.07
|
2010-03-17
|
2010-02-08
|
0.07
|
2010-02-17
|
2010-01-07
|
0.07
|
2010-01-19
|
2009-12-08
|
0.07
|
2009-12-17
|
2009-11-06
|
0.07
|
2009-11-17
|
2009-10-07
|
0.07
|
2009-10-19
|
2009-09-08
|
0.07
|
2009-09-17
|
2009-08-06
|
0.07
|
2009-08-17
|
2009-07-08
|
0.07
|
2009-07-17
|
2009-06-08
|
0.07
|
2009-06-17
|
2009-05-07
|
0.07
|
2009-05-18
|
2009-04-08
|
0.07
|
2009-04-20
|
2009-03-06
|
0.06
|
2009-03-17
|
2009-02-06
|
0.06
|
2009-02-17
|
2009-01-08
|
0.06
|
2009-01-20
|
2008-12-08
|
0.06
|
2008-12-17
|
2008-11-06
|
0.06
|
2008-11-17
|
2008-10-08
|
0.06
|
2008-10-17
|
2008-09-08
|
0.06
|
2008-09-17
|
2008-08-07
|
0.06
|
2008-08-18
|
2008-07-08
|
0.05
|
2008-07-17
|
2008-06-06
|
0.05
|
2008-06-17
|
2008-05-08
|
0.05
|
2008-05-19
|
2008-04-08
|
0.05
|
2008-04-17
|
2008-03-06
|
0.05
|
2008-03-17
|
2008-02-07
|
0.05
|
2008-02-19
|
2008-01-08
|
0.05
|
2008-01-17
|
2007-12-06
|
0.05
|
2007-12-17
|
2007-11-07
|
0.05
|
2007-11-16
|
2007-10-05
|
0.05
|
2007-10-17
|
2007-09-06
|
0.05
|
2007-09-17
|
2007-08-08
|
0.05
|
2007-08-17
|
2007-07-06
|
0.05
|
2007-07-17
|
2007-06-07
|
0.06
|
2007-06-18
|
2007-05-08
|
0.06
|
2007-05-17
|
2007-04-05
|
0.06
|
2007-04-17
|
2007-03-08
|
0.06
|
2007-03-19
|
2007-02-08
|
0.06
|
2007-02-20
|
2007-01-08
|
0.06
|
2007-01-17
|
2006-12-07
|
0.06
|
2006-12-18
|
2006-11-08
|
0.06
|
2006-11-17
|
2006-10-05
|
0.06
|
2006-10-17
|
2006-09-07
|
0.06
|
2006-09-18
|
2006-08-08
|
0.06
|
2006-08-17
|
2006-07-06
|
0.06
|
2006-07-17
|
2006-06-08
|
0.06
|
2006-06-19
|
2006-05-08
|
0.06
|
2006-05-17
|
2006-04-06
|
0.06
|
2006-04-17
|
2006-03-08
|
0.06
|
2006-03-17
|
2006-02-08
|
0.06
|
2006-02-17
|
2006-01-06
|
0.06
|
2006-01-17
|
2005-12-08
|
0.07
|
2005-12-19
|
2005-11-08
|
0.07
|
2005-11-17
|
2005-10-06
|
0.07
|
2005-10-18
|
2005-09-07
|
0.07
|
2005-09-16
|
2005-08-08
|
0.07
|
2005-08-17
|
2005-07-07
|
0.07
|
2005-07-18
|
2005-06-07
|
0.07
|
2005-06-16
|
2005-05-05
|
0.07
|
2005-05-16
|
2005-04-07
|
0.08
|
2005-04-18
|
2005-03-07
|
0.08
|
2005-03-16
|
2005-02-07
|
0.08
|
2005-02-16
|
2005-01-06
|
0.08
|
2005-01-18
|
2004-12-07
|
0.08
|
2004-12-16
|
2004-11-04
|
0.08
|
2004-11-15
|
2004-10-06
|
0.08
|
2004-10-18
|
2004-09-08
|
0.08
|
2004-09-17
|
2004-08-05
|
0.08
|
2004-08-16
|
2004-07-07
|
0.08
|
2004-07-16
|
2004-06-04
|
0.08
|
2004-06-15
|
2004-05-06
|
0.08
|
2004-05-17
|
2004-04-07
|
0.08
|
2004-04-16
|
2004-03-04
|
0.08
|
2004-03-16
|
2004-02-06
|
0.08
|
2004-02-17
|
2004-01-07
|
0.08
|
2004-01-16
|
2003-12-05
|
0.08
|
2003-12-16
|
2003-11-06
|
0.08
|
2003-11-17
|
2003-10-07
|
0.08
|
2003-10-16
|
2003-09-04
|
0.08
|
2003-09-15
|
2003-08-07
|
0.08
|
2003-08-18
|
2003-07-07
|
0.08
|
2003-07-16
|
2003-06-05
|
0.08
|
2003-06-16
|
2003-05-07
|
0.08
|
2003-05-16
|
2003-04-07
|
0.08
|
2003-04-16
|
2003-03-06
|
0.08
|
2003-03-17
|
2003-02-06
|
0.08
|
2003-02-18
|
2003-01-07
|
0.08
|
2003-01-16
|
2002-12-05
|
0.08
|
2002-12-16
|
2002-11-07
|
0.08
|
2002-11-19
|
2002-10-07
|
0.08
|
2002-10-16
|
2002-09-05
|
0.08
|
2002-09-16
|
2002-08-07
|
0.08
|
2002-08-16
|
2002-07-03
|
0.08
|
2002-07-15
|
2002-06-06
|
0.08
|
2002-06-17
|
2002-05-07
|
0.08
|
2002-05-16
|
2002-04-05
|
0.08
|
2002-04-16
|
2002-03-07
|
0.08
|
2002-03-18
|
2002-02-07
|
0.08
|
2002-02-19
|
2002-01-07
|
0.07
|
2002-01-16
|
2001-12-06
|
0.07
|
2001-12-17
|
2001-11-07
|
0.07
|
2001-11-16
|
2001-10-03
|
0.06
|
2001-10-15
|
2001-09-06
|
0.06
|
2001-09-17
|
2001-08-08
|
0.06
|
2001-08-17
|
2001-07-05
|
0.06
|
2001-07-16
|
2001-06-07
|
0.06
|
2001-06-18
|
2001-05-07
|
0.06
|
2001-05-16
|
2001-04-05
|
0.06
|
2001-04-16
|
2001-03-07
|
0.06
|
2001-03-16
|
2001-02-07
|
0.06
|
2001-02-16
|
2001-01-05
|
0.06
|
2001-01-16
|
2000-12-07
|
0.06
|
2000-12-18
|
2000-11-08
|
0.06
|
2000-11-17
|
2000-10-04
|
0.06
|
2000-10-16
|
2000-09-07
|
0.06
|
2000-09-18
|
2000-08-08
|
0.06
|
2000-08-17
|
2000-07-06
|
0.06
|
2000-07-17
|
2000-06-07
|
0.06
|
2000-06-16
|
2000-05-04
|
0.06
|
2000-05-15
|
2000-04-06
|
0.06
|
2000-04-17
|
2000-03-08
|
0.06
|
2000-03-17
|
2000-02-08
|
0.06
|
2000-02-17
|
2000-01-06
|
0.06
|
2000-01-18
|
1999-12-08
|
0.06
|
1999-12-17
|
1999-11-05
|
0.06
|
1999-11-16
|
1999-10-06
|
0.06
|
1999-10-18
|
1999-09-08
|
0.06
|
1999-09-17
|
1999-08-05
|
0.06
|
1999-08-16
|
1999-07-02
|
0.06
|
1999-07-14
|
1999-06-03
|
0.06
|
1999-06-14
|
1999-05-06
|
0.06
|
1999-05-17
|
1999-04-05
|
0.06
|
1999-04-13
|
